110 related articles for article (PubMed ID: 37990902)
1. Identification of Novel Signals Associated with US-FDA Approved Drugs (2013) Using Disproportionality Analysis.
Raghuvanshi S; Rahman MA; Posa MK; Kumar A
Curr Drug Saf; 2023 Nov; ():. PubMed ID: 37990902
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system.
Wu Z; Zhou P; He N; Zhai S
Front Cardiovasc Med; 2022; 9():966331. PubMed ID: 36352852
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: A disproportionality analysis.
Sharma A; Kumar A
Acta Neurol Scand; 2022 Nov; 146(5):623-627. PubMed ID: 36029138
[TBL] [Abstract][Full Text] [Related]
4. Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database.
Nair HP; Kulkarni AR; Eswaran M; Subeesh V
Arab J Gastroenterol; 2023 Feb; 24(1):1-4. PubMed ID: 36725376
[TBL] [Abstract][Full Text] [Related]
5. Identification of Signal of Clindamycin Associated Renal Failure Acute: A Disproportionality Analysis.
Javed F; Kumar A
Curr Drug Saf; 2024; 19(1):123-128. PubMed ID: 36852785
[TBL] [Abstract][Full Text] [Related]
6. Urinary tract infections and genital mycotic infections associated with SGLT‑2 inhibitors: an analysis of the FDA Adverse Event Reporting System.
Yang T; Zhou Y; Cui Y
Expert Opin Drug Saf; 2023 Nov; ():1-6. PubMed ID: 38009230
[TBL] [Abstract][Full Text] [Related]
7. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
8. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
9. Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysis.
Tyagi S; Kumar A
Crit Rev Oncol Hematol; 2024 May; 200():104398. PubMed ID: 38810844
[TBL] [Abstract][Full Text] [Related]
10. Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).
Woods RH
Br J Clin Pharmacol; 2023 Aug; 89(8):2386-2395. PubMed ID: 36321844
[TBL] [Abstract][Full Text] [Related]
11. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization.
Huynh-Le MP; Shults RC; Connor MJ; Hattangadi-Gluth JA
Clin Genitourin Cancer; 2020 Jun; 18(3):192-200.e2. PubMed ID: 31902714
[TBL] [Abstract][Full Text] [Related]
12. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
[No Abstract] [Full Text] [Related]
13. Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database.
Li J; Wang Y; Yang X; Zhu H; Jiang Z
Expert Opin Drug Saf; 2023 Nov; ():1-7. PubMed ID: 37909653
[TBL] [Abstract][Full Text] [Related]
14. Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system.
Wei W; Chen L; Zhou H; Liu J; Zhang Y; Feng S; Bai Y; Leng Y; Chang E; Huang L
Front Pharmacol; 2023; 14():1208456. PubMed ID: 37645441
[No Abstract] [Full Text] [Related]
15. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
16. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
[TBL] [Abstract][Full Text] [Related]
17. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
[No Abstract] [Full Text] [Related]
18. Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.
Stottlemyer BA; McDermott MC; Minogue MR; Gray MP; Boyce RD; Kane-Gill SL
Ther Adv Drug Saf; 2023; 14():20420986231181334. PubMed ID: 37332887
[TBL] [Abstract][Full Text] [Related]
19. Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database.
Li H; Zhang M; Jiao X; Zhu Y; Liu Y; Zeng L; Wang H; Zhang L; Zhang W; Zhang L
Sci Rep; 2023 Mar; 13(1):4475. PubMed ID: 36934109
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.
Palapra H; Viswam SK; Kalaiselvan V; Undela K
Int J Clin Pharm; 2022 Dec; 44(6):1425-1433. PubMed ID: 36224513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
